00:00If the speaker goes back to Sibu, don't miss him.
00:07My first question. Minister, please answer.
00:17Thank you, Your Excellency.
00:19Thank you, my friend.
00:21Peace be upon you.
00:24I will start with the honourable introduction.
00:27May peace and blessings of Allah be upon you all.
00:30Alright.
00:33My first question is related to the amount of money spent by the Ministry of Health of Malaysia
00:39in the purchase of medicines for hospitals and clinics since 2015
00:46and an estimate for the next five years.
00:50In short, I can mention
00:53the Statistic Report of the Pharmacy Service Programme,
00:56the amount of money spent,
00:58the amount of medicines provided by the Ministry of Health in 2015 and 2023.
01:03Starting from 2015, it was 2,323,000.
01:08In 2016, it was 2,332,000.
01:15In 2016, it was 2,107,000.
01:21In 2022, it was 3,193,000.
01:30In 2023, it was 3,430,000.
01:40These are the numbers.
01:45Looking at the statistics,
01:47the amount of money spent in the purchase of medicines in 2023
01:51has increased by 30% in 8 years,
01:57which is 3 billion,
01:59compared to 2.3 billion in 2015, which I mentioned earlier.
02:04The increase in financial gains is due to the increase in the price of medicines,
02:10the increase in the number of patients,
02:12and the use of new medicines,
02:14according to the standard,
02:16still in the patent period,
02:18and the price of medicines in the patent period.
02:26The Ministry of Health also stated that the amount of money spent
02:29to meet the needs of medicines in the facilities of the Ministry of Health
02:33will continue to increase in the coming years.
02:37Regarding the second question,
02:39regarding the planning of the Ministry of Health
02:42to ensure the guarantee of medicines for the country
02:45through the development of technology and capacity,
02:48export, location,
02:50we have developed several strategies
02:52based on the National Medicines Basis, or DUNAS,
02:56under the component of access to medicines.
02:59First, ensure the availability of national essential medicine lists,
03:05or EMLs,
03:06to reduce the loss of locations,
03:10as well as to give priority and incentives to them
03:14for the assessment and registration of products.
03:16Second, improve the flow of supply chains
03:20through the development of tracking systems
03:23and tracking, and trace,
03:25with the permission of these pharmaceutical products.
03:27In addition, the Ministry of Health also cooperates with all parties
03:31who are interested in developing the pharmaceutical ecosystem in this country,
03:36starting with discovery, pre-clinical studies, clinical, loss, and so on.
03:42In addition, we also cooperate with various ministries and public agencies,
03:47as well as involving the private sector,
03:49especially industrial players.
03:51Finally, if I may add a little more,
03:54through my involvement,
03:56KKM is trying to identify the strengths and advantages
04:00of the local pharmaceutical industry
04:02to ensure that when we develop action plans
04:05or action plans and strategic collaboration,
04:09ASEAN,
04:10drug security and self-reliance,
04:12or with the permission of assurance and independence,
04:16medicines in ASEAN level.
04:21So that's a little bit of what I want to say.
04:25Finally, when we chair ASEAN,
04:29we will face various initiatives.
04:32And we are also planning policies,
04:36policies that I can mention,
04:38as to incentivize,
04:40with the permission of ASEAN,
04:41to provide incentives
04:43to our local investors,
04:46with the announcement made by the Minister of Finance,
04:51to provide an off-take guarantee
04:55in terms of development and loss,
04:58they will provide or invest from the players.
Comments